[go: up one dir, main page]

FR3063226B1 - Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol - Google Patents

Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol Download PDF

Info

Publication number
FR3063226B1
FR3063226B1 FR1751652A FR1751652A FR3063226B1 FR 3063226 B1 FR3063226 B1 FR 3063226B1 FR 1751652 A FR1751652 A FR 1751652A FR 1751652 A FR1751652 A FR 1751652A FR 3063226 B1 FR3063226 B1 FR 3063226B1
Authority
FR
France
Prior art keywords
paracetamol
pharmaceutical formulation
oral
gingival administration
hydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1751652A
Other languages
English (en)
Other versions
FR3063226A1 (fr
Inventor
Eric Goupil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unither Pharmaceuticals
Original Assignee
Unither Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1751652A priority Critical patent/FR3063226B1/fr
Application filed by Unither Pharmaceuticals filed Critical Unither Pharmaceuticals
Priority to RU2019130436A priority patent/RU2771084C2/ru
Priority to US16/489,378 priority patent/US11617730B2/en
Priority to CN201880026512.1A priority patent/CN110799216A/zh
Priority to JP2019547455A priority patent/JP2020509045A/ja
Priority to CA3054996A priority patent/CA3054996A1/fr
Priority to EP18707916.5A priority patent/EP3589325A1/fr
Priority to AU2018227030A priority patent/AU2018227030A1/en
Priority to BR112019017825-2A priority patent/BR112019017825A2/pt
Priority to PCT/EP2018/054949 priority patent/WO2018158324A1/fr
Publication of FR3063226A1 publication Critical patent/FR3063226A1/fr
Application granted granted Critical
Publication of FR3063226B1 publication Critical patent/FR3063226B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à une formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracétamol consistant en une solution hydro-alcoolique comprenant du paracétamol dissous, caractérisée en ce que : ▪ la masse de paracétamol est comprise entre 95 mg et 190 mg, ▪ le volume de ladite solution hydro-alcoolique est compris entre 1,0 mL et 2,0 mL ▪ le degré d'alcool de ladite solution hydro-alcoolique est compris entre 48,5° et 52,5°, et la concentration en paracétamol dans ladite solution hydro-alcoolique est comprise entre 85 mg/mL et 110 mg/mL. La présente invention concerne également ladite formulation pharmaceutique pour son utilisation pour accélérer le passage de la barrière hémato-encéphalique par le paracétamol, et pour son utilisation comme médicament, notamment pour le traitement symptomatique des douleurs ou des états fébriles.
FR1751652A 2017-02-28 2017-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol Expired - Fee Related FR3063226B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1751652A FR3063226B1 (fr) 2017-02-28 2017-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol
BR112019017825-2A BR112019017825A2 (pt) 2017-02-28 2018-02-28 Formulação farmacêutica
CN201880026512.1A CN110799216A (zh) 2017-02-28 2018-02-28 用于通过颊内/齿龈途径施用扑热息痛的药物制剂
JP2019547455A JP2020509045A (ja) 2017-02-28 2018-02-28 頬側／歯肉経路によりパラセタモールを投与するための医薬製剤
CA3054996A CA3054996A1 (fr) 2017-02-28 2018-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol
EP18707916.5A EP3589325A1 (fr) 2017-02-28 2018-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol
RU2019130436A RU2771084C2 (ru) 2017-02-28 2018-02-28 Фармацевтическая композиция для буккального/десенного введения парацетамола
US16/489,378 US11617730B2 (en) 2017-02-28 2018-02-28 Pharmaceutical formulation for administering paracetamol by buccal/gingival route
PCT/EP2018/054949 WO2018158324A1 (fr) 2017-02-28 2018-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol
AU2018227030A AU2018227030A1 (en) 2017-02-28 2018-02-28 Pharmaceutical formulation for administering paracetamol by buccal/gingival route

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1751652 2017-02-28
FR1751652A FR3063226B1 (fr) 2017-02-28 2017-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol

Publications (2)

Publication Number Publication Date
FR3063226A1 FR3063226A1 (fr) 2018-08-31
FR3063226B1 true FR3063226B1 (fr) 2020-05-08

Family

ID=59520975

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1751652A Expired - Fee Related FR3063226B1 (fr) 2017-02-28 2017-02-28 Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol

Country Status (10)

Country Link
US (1) US11617730B2 (fr)
EP (1) EP3589325A1 (fr)
JP (1) JP2020509045A (fr)
CN (1) CN110799216A (fr)
AU (1) AU2018227030A1 (fr)
BR (1) BR112019017825A2 (fr)
CA (1) CA3054996A1 (fr)
FR (1) FR3063226B1 (fr)
RU (1) RU2771084C2 (fr)
WO (1) WO2018158324A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1363600E (pt) * 2001-02-15 2008-12-22 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
FR2910317B1 (fr) * 2006-12-21 2009-02-13 Philippe Perovitch Forme galenique pour l'administration par voie transmuqueuse de paracetamol
FR2940911B1 (fr) 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
CN103961312A (zh) * 2014-05-26 2014-08-06 王学重 一种扑热息痛口服液及其制备方法

Also Published As

Publication number Publication date
WO2018158324A1 (fr) 2018-09-07
RU2019130436A (ru) 2021-03-30
AU2018227030A1 (en) 2019-10-17
US20190374488A1 (en) 2019-12-12
JP2020509045A (ja) 2020-03-26
RU2019130436A3 (fr) 2021-06-04
CN110799216A (zh) 2020-02-14
EP3589325A1 (fr) 2020-01-08
FR3063226A1 (fr) 2018-08-31
US11617730B2 (en) 2023-04-04
BR112019017825A2 (pt) 2020-03-31
RU2771084C2 (ru) 2022-04-26
CA3054996A1 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
MA37616A1 (fr) Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
MA44206A (fr) Comprimé orodispersible comprenant estetrol
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
WO2020072602A1 (fr) Compositions pharmaceutiques comprenant des agents thérapeutiques otiques et procédés associés
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
JP2019510757A (ja) ポリクオタニウムを含む抗菌性組成物
FR3063226B1 (fr) Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol
US20190133995A1 (en) Methods for the treatment of infection
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab
EP4230209A4 (fr) Composition pharmaceutique, formulation combinée pharmaceutique et kit de formulation combinée pour la prévention ou le traitement de l'hépatite b chronique, comprenant chacun, en tant que principe actif, un agent antiviral oral et un vaccin thérapeutique comprenant un lipopeptide et un adjuvant poly(i:c)
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
RU2337684C1 (ru) Способ лечения поздних форм нейросифилиса
WO2020044114A3 (fr) Composition pharmaceutique de méthotrexate
JP5019923B2 (ja) プラノプロフェン含有医薬組成物
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
ES2719054T3 (es) Tratamiento de lesiones cutáneas asociadas a enfermedades autoinmunitarias e inflamatorias con el compuesto de arsénico As2O5
US9744192B2 (en) Methods of treating chronic rhinosinusitis
RU2538433C1 (ru) Фармацевтическая композиция для профилактики и лечения инфекционно-воспалительных заболеваний различной этиологии путем оромукозного введения

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180831

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20241005